WELCURE DRUGS & PHARMACEUTICAL is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 25 | 366 |
| EBITDA (ex other income) | 0 | (0) | (0) | 1 | (7) |
| margin % | 22.5 | — | — | 3.6 | (1.9) |
| Owners' profit | 0 | 0 | (0) | 2 | (5) |
| EPS, as reported (₹) | 0.02 | 0.00 | (0.13) | 0.36 | 0.04 |
| ROE % · ROCE % | 25.4 · 25.4 | 6.7 · 6.7 | (13.1) · (13.1) | 2.1 · 1.2 | (5.7) · (1.9) |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 1.20 | 0.00 |
| Cash from operations | 0 | 0 | (0) | (222) | 2 |
| Capex | 0 | 0 | 0 | (0) | 0 |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 25 | 9 | 21 | 300 | 66 | 0 | 0 |
| Profit before tax | (0) | 2 | 1 | 3 | 31 | 11 | 1 | (50) |
| Net profit | — | 2 | 0 | 3 | 23 | 9 | 1 | (50) |
| EPS (₹) | 0.26 | 0.16 | 0.04 | 0.33 | 2.07 | 0.76 | 0.13 | 0.40 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Agriculture | 67 | 18.3 |
| Trading in Agriculture Produce | 300 | 81.7 |
| Total, before eliminations | 367 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 14 Jul 2026 · Board approves closure of Ahmedabad Corporate Office | board shareholder meetings | medium | — | — |
| 19 Jun 2026 · Company Secretary Palak Jain resigns from Welcure Drugs | management changes | medium | — | — |
| 19 Jun 2026 · Company Secretary Palak Jain resigns from Welcure Drugs | board shareholder meetings | low | — | — |
| 1 Jun 2026 · Newspaper Clipping of Audited Financials Results for the 4th Quarter and Annual year ended 31st March, 2026. | compliance | minimal | — | — |
| 30 May 2026 · Submission of Annual Secretarial Compliance Report for the year ended 31st March. 2026. | compliance | minimal | — | — |
| 29 May 2026 · Audited Standalone Financial Results for the Quarter and Year Ended 31st March, 2026 | results | high | — | — |
| 29 May 2026 · Outcome of the Meeting of Board of Directors of the Company held on today i.e. Friday, 29th May, 2026 | board shareholder meetings | low | — | — |
| 22 May 2026 · Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial .... | results | medium | — | — |
| 23 Apr 2026 · <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... | compliance | minimal | — | — |
| 3 Apr 2026 · Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the 4th Quarter and Annual year ended 31st MArch, 2026. | compliance | minimal |
| 14.74 |
| 63.7 |
| 15.3 |
| 18.8 |
| 8.7 |
| 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 0.1 | 28.9 | 1 of 169 | 100% |
| P/B | 0.3 | 3.3 | 2 of 163 | 99% |
| ROCE | (1.9) | 10.8 | 158 of 183 | 14% |
| ROE | (5.7) | 10.4 | 156 of 171 | 9% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| Revenue growth | (100.0) | 16.3 | 157 of 161 | 0% |
| Profit growth | (2063.6) | 30.9 | 158 of 158 | 0% |
| Market cap | 28 | 839 | 161 of 182 | 12% |
| — |
| — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
